News and Insights

Print this page

Search News & Insights

Matheson Advises Ireland Strategic Investment Fund on Investment in Mainstay Medical

AUTHOR(S): George Brady
DATE: 19.02.2018

Matheson recently advised the Ireland Strategic Investment Fund on its equity investment in Mainstay Medical International plc (“Mainstay”). Mainstay raised a total of approximately €30 million from the Ireland Strategic Investment Fund, existing investors and new investors.

Mainstay is a medical device company focused on bringing to market an innovative implantable neurostimulation system, ReActiv8, for people with disabling Chronic Low Back Pain. The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands, and is listed on the regulated market of the Euronext Paris and the ESM of the Irish Stock Exchange.

Speaking today George Brady, Corporate Partner at Matheson said “we are delighted to have been able to support the Ireland Strategic Investment Fund on this investment”.

The Matheson team was led by George Brady with support from a team of specialists in other areas across the firm.


Matheson Snapshot

About cookies on our website

Following a revised EU directive on website cookies, each company based, or doing business, in the EU is required to notify users about the cookies used on their website.

Our site uses cookies to improve your experience of certain areas of the site and to allow the use of specific functionality like social media page sharing. You may delete and block all cookies from this site, but as a result parts of the site may not work as intended.

To find out more about what cookies are, which cookies we use on this website and how to delete and block cookies, please see our Which cookies we use page.

Click on the button below to accept the use of cookies on this website (this will prevent the dialogue box from appearing on future visits)